For 3.0, there has been a substantial expansion of the content of the database through the addition of new sources and the updating of existing sources. Six new sources have been added, which brings the total number of sources represented by the DGIdb to 30. Three of these new sources provide drug–gene interactions from prominent expert-curated databases of clinically actionable variants similar to the CIViC and Clearity Foundation sources, already included in the DGIdb (Supplementary Table S1) (5). These include the Precision Oncology Knowledge Base (OncoKB), cancer genome interpreter (CGI) and The Jackson Laboratory Clinical Knowledgebase (CKB) (Supplementary Table S1) (6,7). From these three new sources, 2822 new interaction claims were added. These sources were added as anti-neoplastic interaction sources, resulting in an 36.7% increase in anti-neoplastic drugs. Drug–gene interactions were also added from the United States Food and Drug Administration (FDA) Pharmacogenomics website and the National Cancer Institute (NCI) Cancer Gene Index, resulting in an additional 276 and 6231 interaction claims, respectively (Supplementary Table S1). In addition to these sources, the existing druggable gene category sources were expanded with
